Company Encyclopedia
View More
name
Chemomab Therapeutics
CMMB.US
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
1.875 T
CMMB.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chemomab Therapeutics Advances Nebokitug Phase 3 Trial with Regulatory Support

    Chemomab Therapeutics announced significant progress in its nebokitug Phase 3 trial for primary sclerosing cholangitis, receiving positive feedback from the FDA and EMA. The company presented favorable Phase 2 data and is exploring partnering options to support the Phase 3 program. Chemomab expects its cash runway to last through the end of 2026. The latest analyst rating on CMMB stock is a Buy with a $25.00 price target, though TipRanks' AI Analyst rates it as Underperform due to financial challenges.

    Tip Ranks·
    US
    CMMB
    +1.65%
    Tip Ranks·
    US
    CMMB
    +1.65%

    Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update

    Chemomab Therapeutics Ltd:* CHEMOMAB THERAPEUTICS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE* CHEMOMAB THERAPEUTICS LTD - CASH RUNWAY EXPECTED THROUGH END OF Q4 2026 Source text: Further company coverage:

    Reuters·
    US
    CMMB
    +1.65%
    Reuters·
    US
    CMMB
    +1.65%

    Chemomab Reports Positive Phase 2 Data for Nebokitug in Primary Sclerosing Cholangitis

    Chemomab Therapeutics Ltd. announced positive Phase 2 data for nebokitug in primary sclerosing cholangitis (PSC), to be presented at the AASLD The Liver Meeting® 2025 on November 10, 2025. The data includes results from the trial’s open label extension, highlighting nebokitug’s favorable safety profile and improvements in inflammatory and fibrotic biomarkers over 48 weeks. The presentations are designated as Posters of Distinction, providing insights into nebokitug’s macrophage-mediated mechanisms in PSC.

    Reuters·
    US
    CMMB
    +1.65%
    Reuters·
    US
    CMMB
    +1.65%

    Chemomab Therapeutics Advances Phase 3 Plans for Nebokitug

    Chemomab Therapeutics Ltd. is advancing its Phase 3 plans for nebokitug, a monoclonal antibody targeting CCL24, aimed at treating primary sclerosing cholangitis (PSC). The company reported a cash position of $9.5 million, sufficient to fund operations through mid-2026. R&D expenses decreased to $1.3 million, while general and administrative expenses rose to $1.0 million. The net loss for the quarter was $2.1 million. Chemomab is also enhancing its intellectual property with new patents and plans a one-for-four reverse split to strengthen its market position.

    Tip Ranks·
    US
    CMMB
    +1.65%
    Tip Ranks·
    US
    CMMB
    +1.65%

    Upcoming Stock Splits This Week (August 25 to August 29) – Stay Invested

    This week, several companies are implementing reverse stock splits to comply with Nasdaq requirements. Notable splits include Graphjet Technology (1-for-60), Foresight Autonomous (1-for-7), Greenwave Technology (1-for-110), SU Group (1-for-10), Quhuo Limited (1-for-90), OceanPal (1-for-25), Americas Gold and Silver (1-for-2.5), Akanda (1-for-3.125), and Chemomab Therapeutics (1-for-4). These actions aim to boost share prices and attract retail investors while maintaining compliance with exchange standards.

    Tip Ranks·
    US
    QH
    -5.12%
    US
    CMMB
    +1.65%
    Tip Ranks·
    US
    QH
    -5.12%
    US
    CMMB
    +1.65%